JPH03279311A - External preparation of skin - Google Patents
External preparation of skinInfo
- Publication number
- JPH03279311A JPH03279311A JP7745890A JP7745890A JPH03279311A JP H03279311 A JPH03279311 A JP H03279311A JP 7745890 A JP7745890 A JP 7745890A JP 7745890 A JP7745890 A JP 7745890A JP H03279311 A JPH03279311 A JP H03279311A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- glycerin
- base
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000011187 glycerol Nutrition 0.000 claims abstract description 16
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 239000000839 emulsion Substances 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 239000006185 dispersion Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000002585 base Substances 0.000 abstract 1
- 230000000254 damaging effect Effects 0.000 abstract 1
- 239000003883 ointment base Substances 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 description 13
- 239000003205 fragrance Substances 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 101710159621 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase Proteins 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- -1 cyclic oligosaccharide Chemical class 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000001116 FEMA 4028 Substances 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960005066 trisodium edetate Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- NLISGMDYEMTBDX-UHFFFAOYSA-N OCC(O)CO.C(C)C(CCCCC(=O)O)(CC)CC Chemical compound OCC(O)CO.C(C)C(CCCCC(=O)O)(CC)CC NLISGMDYEMTBDX-UHFFFAOYSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 108010059557 kistrin Proteins 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- NGPNWUWGVIIIDG-LEJBHHMKSA-L magnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-yl] phosphate Chemical class [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1OP([O-])([O-])=O NGPNWUWGVIIIDG-LEJBHHMKSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は皮膚外用剤、ざらに詳しくは使用感触に優れ、
保湿効果の高い皮膚外用剤に関する。[Detailed Description of the Invention] [Industrial Field of Application] The present invention provides an external preparation for skin, and more specifically, a preparation for external use on the skin, which has an excellent feel when used,
Concerning external skin preparations with high moisturizing effects.
[従来の技術]
皮膚における水分の保持は皮膚をすこやかに保つ為に欠
かせない要因であり、保湿を目的とした化粧料や医薬品
が数多く市販されている。保湿に関与する物質の研究も
盛んに行なわれ、数々の保湿剤が提供されている。わけ
てもグリセリンは保水性、吸水性に優れていることから
化粧料や医薬品等に汎用されている。[Prior Art] Retention of moisture in the skin is an essential factor for keeping the skin healthy, and many cosmetics and pharmaceuticals aimed at moisturizing are commercially available. Research into substances involved in moisturizing has been actively conducted, and a number of moisturizing agents have been provided. In particular, glycerin has excellent water retention and water absorption properties, so it is widely used in cosmetics and pharmaceuticals.
[発明が解決しようとする課題]
しかしながら、グリセリンは高い保湿能を有するものの
、配合量が多くなるとべたつきなどの使用性面での欠点
か生じ、皮膚外用剤の特性を考慮すると配合量が制限さ
れている。本発明者らは上記事情に鑑み鋭意研究した結
果、ヒドロキシアルキル化シクロデキストリンとグリセ
リンを併用すると、上記欠点が解決できることを見出し
て本発すなわち、ヒドロキシアルキル化シクロデキスト
リンと、グリセリン3重量%〜20重量%とを配合する
ことを特徴とする皮膚外用剤に関するものである。[Problems to be Solved by the Invention] However, although glycerin has a high moisturizing ability, if the amount of glycerin is too large, it may have disadvantages in terms of usability such as stickiness, and the amount of glycerin that can be added is limited when considering the characteristics of external preparations for the skin. ing. The present inventors conducted extensive research in view of the above circumstances, and found that the above drawbacks could be solved by using hydroxyalkylated cyclodextrin and glycerin in combination. The present invention relates to an external preparation for skin, characterized in that it contains % by weight.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明で用いるヒドロキシアルキル化シクロデキストリ
ン(以下HACDと略する)は従来から環状のオリゴ糖
としてよく知られているシクロデキストリンの水溶解性
を増すために水酸基にヒドロキシアルキル基を導入した
ものである。The hydroxyalkylated cyclodextrin (hereinafter abbreviated as HACD) used in the present invention is a cyclodextrin, which is conventionally well known as a cyclic oligosaccharide, and has a hydroxyalkyl group introduced into the hydroxyl group to increase the water solubility. .
ヒドロキシアルキル基としては、主にヒドロキシメチル
、ヒドロキシエチル、ヒドロキシプロピル、ヒドロキシ
ブチル、ジヒドロキシプロピルなどの置換基が使用きれ
、これら置換反応の結果、ヒドロキシメチルシクロデキ
ストリン、ヒドロキシエチルシクロデキストリン、ヒド
ロキシプロピルシクロデキストリン、ヒドロキシブチル
シクロデキストリン、ジヒドロキシプロピルシクロデキ
ストリンなどのHACDを得ることができる。As the hydroxyalkyl group, substituents such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, dihydroxypropyl are mainly used, and as a result of these substitution reactions, hydroxymethylcyclodextrin, hydroxyethylcyclodextrin, hydroxypropylcyclodextrin , hydroxybutylcyclodextrin, dihydroxypropylcyclodextrin, and the like can be obtained.
シクロデキストリン(以下、CDと略する)は、グルコ
ースの数の違いによってα、β、γの構造をもつCD(
以下、α−CD、β−CD、 7−CDと略する。)が
知られているが、本発明はこれらのCDの一種または2
種以上をヒドロキシアルキル化して使用する。普通はβ
−CDを用いるが、α、γ−CDを母核としてもかまわ
ない。α、β、7のCDを同時に含有する澱粉分解物も
使用できる。Cyclodextrin (hereinafter abbreviated as CD) is a CD (hereinafter abbreviated as CD) that has an α, β, and γ structure depending on the number of glucose.
Hereinafter, they will be abbreviated as α-CD, β-CD, and 7-CD. ), but the present invention is directed to one or two of these CDs.
More than one species is hydroxyalkylated and used. Usually β
-CD is used, but α and γ-CD may also be used as the mother nucleus. A starch decomposition product containing α, β, and 7 CDs at the same time can also be used.
これらHACDのうち、価格、製造のしやすき使用性、
水溶解性を考慮した場合、ヒドロキシエチル化β−CD
またはヒドロキシプロピル化β−CDが好ましいが、こ
れらに限定されるものではない。Among these HACDs, price, ease of manufacture, usability,
Considering water solubility, hydroxyethylated β-CD
or hydroxypropylated β-CD is preferred, but is not limited thereto.
また、ヒドロキシエチル化CDまたはヒドロキシプロピ
ル化CDは製造状態においてはα、β、γが混じりあっ
た混合物となっているが、混合物のままでもα、β、7
のヒドロキシプロピル化CDを単離したものでも使用す
ることができる。In addition, hydroxyethylated CD or hydroxypropylated CD is a mixture of α, β, and γ in the manufacturing state, but even as a mixture, α, β, 7
Isolated hydroxypropylated CD can also be used.
HACDの製造方法としては、従来からいくつかの方法
が知られているが、以下に一例を示す。Several methods have been known for manufacturing HACD, and one example will be shown below.
β−CD(日本食品化上製、商標名:セルデックスN)
100gを20%NaOH水溶液1501に溶解し、3
0°Cに保持しつつ酸化プロピレジ501を徐々に滴下
し、20時間撹拌し反応を続ける。反応終了後、塩酸で
p H6,0に中和し、透析膜チューブ中に入れ、流水
下24時間脱塩を行なった。その後凍結乾燥機で乾燥を
行なって、ヒドロキシプロピル化β−シクロデキストリ
ン約90gが得られた。β-CD (manufactured by Nihon Shokuhin Kagaku, trade name: Celldex N)
Dissolve 100g in 20% NaOH aqueous solution 1501,
While maintaining the temperature at 0°C, propylene oxide 501 was gradually added dropwise, and the reaction was continued with stirring for 20 hours. After the reaction was completed, the solution was neutralized to pH 6.0 with hydrochloric acid, placed in a dialysis membrane tube, and desalted under running water for 24 hours. Thereafter, it was dried in a freeze dryer to obtain about 90 g of hydroxypropylated β-cyclodextrin.
このヒドロキシプロピル化β−シクロデキストリンのC
D当たりの1換度は5.1であった。C of this hydroxypropylated β-cyclodextrin
The degree of conversion per D was 5.1.
本発明におけるHACDの配合量は、特に制限はないが
、皮膚外用剤全量中0.1重量%(以下%とする)〜1
0%であり、好ましくは1%〜5%である。0.1%未
満ではその効果は発揮されず、10%を越えると使用性
のべたつきが出るので使用感改善効果が弱くなる。The blending amount of HACD in the present invention is not particularly limited, but is 0.1% by weight (hereinafter referred to as %) to 1% by weight based on the total amount of the skin external preparation.
0%, preferably 1% to 5%. If it is less than 0.1%, the effect will not be exhibited, and if it exceeds 10%, the usability will become sticky and the effect of improving the feeling of use will be weakened.
HACDばそのまま本発明の化粧料中に配合してもよい
し、HACDの中に油分、紫外線吸収剤、香料等の、水
に難溶性の成分をあらかじめ包接してから配合しても良
い。HACD may be blended into the cosmetic of the present invention as it is, or ingredients that are poorly soluble in water, such as oils, ultraviolet absorbers, and fragrances, may be included in HACD in advance and then blended.
本発明で用いるグリセリンは分子内に3個の水酸基を有
する多価アルコールの一種である。Glycerin used in the present invention is a type of polyhydric alcohol having three hydroxyl groups in the molecule.
本発明の皮膚外用剤へのグリセリンの配合量は、3%〜
20%であり、好ましくは5%〜15%である。3%未
満ではその効果は発揮きれず、20%を越えると使用性
上べたつきが出て好ましくない。The amount of glycerin added to the skin external preparation of the present invention is 3% to
20%, preferably 5% to 15%. If it is less than 3%, the effect cannot be fully exhibited, and if it exceeds 20%, it becomes sticky in terms of usability, which is not preferable.
本発明の皮膚外用剤は前記の必須成分に加えて必要に応
じて、本発明の効果を損なわない範囲で、化粧品、医薬
品等に一般に用いられる各種成分、すなわち水性成分、
粉末成分、油分、界面活性剤、保湿剤、増粘剤、防腐剤
、酸化防止剤、香料、色材、紫外線吸収剤、薬剤等を配
合することができる。In addition to the above-mentioned essential ingredients, the external skin preparation of the present invention may optionally contain various ingredients commonly used in cosmetics, pharmaceuticals, etc., i.e., aqueous ingredients, to the extent that the effects of the present invention are not impaired.
Powder components, oils, surfactants, humectants, thickeners, preservatives, antioxidants, fragrances, colorants, ultraviolet absorbers, drugs, etc. can be blended.
また本発明の皮膚外用剤の剤型は任意であり、例えば化
粧水系の可溶化系、乳液、クリーム等の乳化系あるいは
軟膏、分散液、粉末製品などの剤型をとることができる
。Further, the dosage form of the skin external preparation of the present invention is arbitrary, and may be, for example, a solubilized skin lotion type, an emulsified type such as a milky lotion or a cream, or a dosage form such as an ointment, a dispersion liquid, or a powder product.
[実施例]
以下本発明を実施例および比較例を挙げて詳細に説明す
る。本発明は、これによって限定されるものではない。[Examples] The present invention will be described in detail below with reference to Examples and Comparative Examples. The present invention is not limited thereby.
配合量は重量%である。なお、効果の測定は以下の方法
によった。The blending amount is in weight%. The effect was measured using the following method.
しっとりさ、べたつきのなぎ の
専門パネル10名により、調製した試料を実際に使用し
、官能試験を行なった。評価結果は、次の表示で示すこ
とにする。A sensory test was conducted using the prepared samples by a panel of 10 experts on moistness and stickiness. The evaluation results will be shown in the following format.
o:10名中8名以上が良好と回答したO:10名中6
名以上が良好と回答した△:10名中4老中4名以上と
回答した×:10名中4名未満が良好と回答した実施例
1、比較例1〜3
表1に示す処方で化粧水を常法により製造した。o: More than 8 out of 10 people answered that it was good O: 6 out of 10 people
△: 4 out of 10 people answered that it was good. ×: Less than 4 out of 10 people answered that it was good. Example 1, Comparative Examples 1 to 3 Makeup with the formula shown in Table 1 Water was prepared by conventional methods.
表1から明らかなように実施例1は保湿効果に優れ、べ
たつきもなく、しかも肌の状態も良くなったように感じ
られるものであった。As is clear from Table 1, Example 1 had an excellent moisturizing effect, was not sticky, and the skin condition seemed to be improved.
実施例2 クリーム
A、ステアリン酸 10.0ステ
アリルアルコール 4.0ステアリン酸ブ
チル 8.0グリセリントリエチル
ヘキサノエート2.0
香料 0.4防腐剤
適量B、ジプロピレングリ
コール 10.Oグリセリン
20.0ヒドロキシプロピル化β−
シクロデキストリン 10.0
水酸化カリウム 0.4エデト酸
三ナトリウム 0.05精製水
残余Aの油相部とBの水相部をそ
れぞれ70°Cに加熱し完全溶解する。A相をB相に加
えて、乳化機で乳化する。乳化物を熱交換機を用いて冷
却してクリームを得た。このクリームはしっとりとして
べたつきもなく、保湿効果に優れるものであった。Example 2 Cream A, stearic acid 10.0 Stearyl alcohol 4.0 Butyl stearate 8.0 Glycerin triethylhexanoate 2.0 Fragrance 0.4 Preservatives
Appropriate amount B, dipropylene glycol 10. O glycerin
20.0 Hydroxypropylated β-cyclodextrin 10.0 Potassium hydroxide 0.4 Trisodium edetate 0.05 Purified water
The remaining oil phase part A and water phase part B are each heated to 70°C to completely dissolve them. Add phase A to phase B and emulsify with an emulsifier. The emulsion was cooled using a heat exchanger to obtain cream. This cream was moist, non-sticky, and had excellent moisturizing effects.
実施例3 美白クリーム
A、セタノール
ワセリン
イソプロピルミリステート
スクワラン
ステアリン酸モノ
グリセリンエステル
POE (20モル)ソルビタン
モノステアレート
香料
ビタミンEアセテート
防腐剤
B、グリセリン
ヒドロキシエチル化
β−シクロデキストリン
ジプロピレングリコール
4.0
7.0
8.0
15.0
2.2
2.8
0.3
0.05
適量
3.0
5.0
5.0
エデト酸二ナトリウム 0.01アスコ
ルビン酸リン酸マグネシウム塩 3.0精製水
残余実施例2に準じてクリームを
得た。 このものは保湿効果に優れ、べたつきのない使
用感触の良いものであった。Example 3 Whitening Cream A, Cetanol Petrolatum Isopropyl Myristate Squalane Stearic Acid Monoglycerin Ester POE (20 mol) Sorbitan Monostearate Fragrance Vitamin E Acetate Preservative B, Glycerin Hydroxyethylated β-Cyclodextrin Dipropylene Glycol 4.0 7 .0 8.0 15.0 2.2 2.8 0.3 0.05 Adequate amount 3.0 5.0 5.0 Edetate disodium 0.01 Ascorbic acid phosphate magnesium salt 3.0 Purified water
A cream was obtained according to the rest of Example 2. This product had an excellent moisturizing effect and was non-sticky and had a good feel when used.
実施例4 乳液
A、スクワラン
オレイルオレート
ワセリン
ソルビタンセスキオレイン酸エステル
ポリオキシエチレン(20モル)
オレイルエーテル
香料
防腐剤
B、1.3ブチレングリコール
ヒドロキシプロビル化
β−シクロデキストリン
グリセリン
5.0
3.0
2.0
0.8
1.2
0.3
適量
5.0
0.1
3.0
エタノール 3.0力ルボキ
シビニルボルリマ−0,2
水酸化カリウム 0.1へキサメ
タリン酸ナトリウム 0.05精製水
残余実施例2に準じて乳液を得た
。Example 4 Emulsion A, squalane oleyl oleate vaseline sorbitan sesquioleate polyoxyethylene (20 mol) oleyl ether fragrance preservative B, 1.3 butylene glycol hydroxyprobylated β-cyclodextrin glycerin 5.0 3.0 2 .0 0.8 1.2 0.3 Appropriate amount 5.0 0.1 3.0 Ethanol 3.0 Ruboxyvinylborrimer 0.2 Potassium hydroxide 0.1 Sodium hexametaphosphate 0.05 Purified water
A milky lotion was obtained according to the rest of Example 2.
このものは保湿効果に優れ、べたつきのない使用感触の
良いものであった。This product had an excellent moisturizing effect and was non-sticky and had a good feel when used.
実施例5 ファンデーション
A、セタノール
脱臭ラノリン
ホホバ油
ワセリン
スクワラン
ステアリン酸モノ
グリセリンエステル
ステアリルグリチルレチネート
POE (60モル)硬化ヒマシ油
POE (20モル)セチルエーテル
3.5
4.0
5.0
2.0
6.0
2.5
0.01
1.5
1.0
防腐剤 適量香料
0.3B、ヒドロキシプロピ
ル化
シクロデキストリン混合物 5.0
グリセリン 15.0調合粉末
12.0エデト酸三ナトリ
ウム 0.2精製水
残余実施例2に準じてファンデーションを得
た。Example 5 Foundation A, cetanol deodorized lanolin jojoba oil vaseline squalane stearic acid monoglycerin ester stearyl glycyrrhetinate POE (60 mol) hydrogenated castor oil POE (20 mol) cetyl ether 3.5 4.0 5.0 2.0 6.0 2.5 0.01 1.5 1.0 Preservatives Appropriate amount of fragrance
0.3B, hydroxypropylated cyclodextrin mixture 5.0 Glycerin 15.0 Mixed powder 12.0 Trisodium edetate 0.2 Purified water
A foundation was obtained according to the rest of Example 2.
このものは保湿効果に優れ、べたつきのない使用感触の
良いものであった。This product had an excellent moisturizing effect and was non-sticky and had a good feel when used.
実施例6 化粧水
A、エタノール
POE (20モル)オレイル
アルコールエーテル
2−エチルへキシル−P−ジメチル
アミノベンゾエート
5.0
2.0
0.18
香料
B、1.3ブチレングリコール
0.05
10.0
ヒドロキシメチル化
β−シクロデキストリン 1.0
グリセリン 5.0精製水
残余Aのアルコール相をBの
水相に添加し、可溶化して化粧水を得た。Example 6 Lotion A, ethanol POE (20 mol) oleyl alcohol ether 2-ethylhexyl-P-dimethylaminobenzoate 5.0 2.0 0.18 Fragrance B, 1.3 butylene glycol 0.05 10.0 Hydroxymethylated β-cyclodextrin 1.0 Glycerin 5.0 Purified water
The remaining alcohol phase of A was added to the aqueous phase of B and solubilized to obtain a lotion.
このものは、しっとりとしてもなからべたつきのない使
用感触で、保湿効果の高いものであった。This product felt moist but not sticky at all, and had a high moisturizing effect.
実施例7 ヘアートニック
A、エタノール
POE(100モル)硬化ヒマシ油
ニンジン抽出液
ヘチマ抽出液
香料
B、グリセリン
ヒドロキシブチル化シク04キストリン混合物2−ヒド
ロキシ−4メトキシペンソヘエノン精製水
実施例6に準じてヘアートニックを得た。Example 7 Hair tonic A, ethanol POE (100 mol) Hydrogenated castor oil Carrot extract Loofah extract Fragrance B, Glycerin Hydroxybutylated Cyc04 Kistrin mixture 2-Hydroxy-4 methoxypensohenone Purified water According to Example 6 Got a hair tonic.
60.0
2.0
0.1
0.1
0.2
3.0
1.0
0.1
残余
このものは、しっとりとしてもなからべたつきのない使
用感触で、保湿効果の高いものであった。60.0 2.0 0.1 0.1 0.2 3.0 1.0 0.1 Remaining This product had a moist but non-sticky feel and had a high moisturizing effect.
[発明の効果]
本発明の皮膚外用剤は、ヒドロキシアルキル化シクロデ
キストリンとグリセリンを配合することにより、使用感
触に優れ、保湿効果の高いものが得られる。[Effects of the Invention] By blending hydroxyalkylated cyclodextrin and glycerin, the skin external preparation of the present invention has an excellent feel when used and has a high moisturizing effect.
Claims (1)
リセリン3重量%〜20重量%とを配合することを特徴
とする皮膚外用剤。(1) An external preparation for skin, characterized in that it contains hydroxyalkylated cyclodextrin and 3% to 20% by weight of glycerin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7745890A JP2938120B2 (en) | 1990-03-27 | 1990-03-27 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7745890A JP2938120B2 (en) | 1990-03-27 | 1990-03-27 | External preparation for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03279311A true JPH03279311A (en) | 1991-12-10 |
JP2938120B2 JP2938120B2 (en) | 1999-08-23 |
Family
ID=13634569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7745890A Expired - Lifetime JP2938120B2 (en) | 1990-03-27 | 1990-03-27 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2938120B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010059115A (en) * | 2008-09-05 | 2010-03-18 | Shiseido Co Ltd | Skin care method |
-
1990
- 1990-03-27 JP JP7745890A patent/JP2938120B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010059115A (en) * | 2008-09-05 | 2010-03-18 | Shiseido Co Ltd | Skin care method |
Also Published As
Publication number | Publication date |
---|---|
JP2938120B2 (en) | 1999-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3023078B2 (en) | Cosmetic and / or dermatological composition containing crosslinked poly (2-acrylamido-2-methylpropanesulfonic acid) and at least one active ingredient precursor | |
KR0159271B1 (en) | Cosmetics containing inclusion product with hydroxyalkylated cyclodextrin and powder cosmetics thereof | |
US9072683B2 (en) | Use of xanthan gum as a hair fixative | |
JP2018500345A (en) | Use of fatty acid esters and compositions containing these esters to impart a matte feel to the skin | |
JPH1067639A (en) | Vitamin e-vitamin c phosphoric diester/cyclodextrin clathrate and external preparation for skin containing the same | |
JPH08176587A (en) | Perfume composition | |
JP2972039B2 (en) | Cosmetics | |
JP2941880B2 (en) | Emulsified cosmetic | |
JPS61167608A (en) | Cosmetic | |
JP2916689B2 (en) | Cosmetics | |
JPH03279311A (en) | External preparation of skin | |
JP2002060315A (en) | Ascorbic acid-containing thickening composition | |
JP3505003B2 (en) | External preparation | |
JP3004675B2 (en) | External preparation for skin | |
JP2929108B2 (en) | Cosmetics and powder cosmetics | |
JPH10203949A (en) | Cosmetic | |
JP2867162B2 (en) | Peel-off type pack cosmetics | |
JPH0624934A (en) | Cosmetic | |
JPH11349470A (en) | Composition for external use | |
JPH11292750A (en) | Cosmetic | |
JP3234041B2 (en) | External preparation for skin | |
JP2002284623A (en) | Cosmetics | |
JPH0415763B2 (en) | ||
JP3026616B2 (en) | Whitening cosmetics | |
JPH06122621A (en) | External agent for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080611 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090611 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090611 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100611 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100611 Year of fee payment: 11 |